{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:28:53Z","timestamp":1793734133435,"version":"4.6.1"},"reference-count":87,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The emergence of CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment paradigm for R\/R B-cell NHLs. However, challenges persist in accurately evaluating treatment response and detecting early relapse, necessitating the exploration of novel biomarkers. Circulating tumor DNA (ctDNA) via liquid biopsy is a non-invasive tool for monitoring therapy efficacy and predicting treatment outcomes in B-NHL following CAR-T therapy. By overcoming the limitations of conventional imaging modalities, ctDNA assessments offer valuable insights into response dynamics, molecular mechanisms of resistance, and early detection of molecular relapse. Integration of ctDNA monitoring into clinical practice holds promise for personalized therapeutic strategies, guiding the development of novel targeted therapies, and enhancing patient outcomes. However, standardization of assay methodologies and consensus on clinical response metrics are imperative to unlock the full potential of ctDNA in the management of B-NHL. Prospective validation of ctDNA in clinical trials is necessary to establish its role as a complementary decision aid.<\/jats:p>","DOI":"10.3390\/cancers16101881","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T06:14:42Z","timestamp":1715753682000},"page":"1881","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Circulating Tumor DNA as a Complementary Prognostic Biomarker during CAR-T Therapy in B-Cell Non-Hodgkin Lymphomas"],"prefix":"10.3390","volume":"16","author":[{"given":"Sarah","family":"Monick","sequence":"first","affiliation":[{"name":"Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene Maraleucel for Patients with Relapsed or Refractory Large B-Cell Lymphomas (TRANSCEND NHL 001): A Multicentre Seamless Design Study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Follicular Lymphoma: The Phase 2 ELARA Trial","volume":"28","author":"Fowler","year":"2021","journal-title":"Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5): A Single-Arm, Multicentre, Phase 2 Trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_7","unstructured":"(2024, February 06). YESCARTA (Axicabtagene Ciloleucel)|FDA, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/yescarta-axicabtagene-ciloleucel."},{"key":"ref_8","unstructured":"(2024, February 06). TECARTUS (Brexucabtagene Autoleucel)|FDA, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/tecartus-brexucabtagene-autoleucel."},{"key":"ref_9","unstructured":"(2024, February 06). BREYANZI (Lisocabtagene Maraleucel)|FDA, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/breyanzi-lisocabtagene-maraleucel."},{"key":"ref_10","unstructured":"(2024, February 06). KYMRIAH (Tisagenlecleucel)|FDA, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/kymriah-tisagenlecleucel."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1): A Single-Arm, Multicentre, Phase 1-2 Trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1200\/JCO.2017.74.5281","article-title":"Minimal Residual Disease Assessment in Lymphoma: Methods and Applications","volume":"35","author":"Herrera","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kuhnl, A., Kirkwood, A.A., O\u2019Reilly, M., Sanderson, R., Tholouli, E., Patel, A., Besley, C., Iyengar, S., Jones, C., and Latif, A.-L. (2021). Outcome of large B-cell lymphoma patients failing CD19 targeted CAR-T therapy. Hematol. Oncol., 39.","DOI":"10.1002\/hon.87_2879"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s12032-014-0446-1","article-title":"Predictive Value of F-18 FDG PET\/CT Quantization Parameters in Diffuse Large B Cell Lymphoma: A Meta-Analysis with 702 Participants","volume":"32","author":"Xie","year":"2015","journal-title":"Med. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Guo, B., Tan, X., Ke, Q., and Cen, H. (2019). Prognostic Value of Baseline Metabolic Tumor Volume and Total Lesion Glycolysis in Patients with Lymphoma: A Meta-Analysis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0210224"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High Metabolic Tumor Volume Is Associated with Decreased Efficacy of Axicabtagene Ciloleucel in Large B-Cell Lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.clml.2023.09.005","article-title":"Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-Cell NHL","volume":"24","author":"Rojek","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00259-018-4171-4","article-title":"FDG PET\/CT for Assessing Tumour Response to Immunotherapy: Report on the EANM Symposium on Immune Modulation and Recent Review of the Literature","volume":"46","author":"Aide","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed\/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s11307-021-01627-8","article-title":"18F-Fluorodeoxyglucose Positron Emission Tomography\/Computed Tomography Following Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma","volume":"23","author":"Ruff","year":"2021","journal-title":"Mol. Imaging Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification Lymphoma Response Criteria in the Era of Immunomodulatory Therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/10428194.2022.2161304","article-title":"Flare-up Phenomenon or Pseudoprogression after CAR T-Cell Infusion in Non-Hodgkin Aggressive Lymphomas","volume":"64","author":"Sortais","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41409-020-01156-y","article-title":"Immune Imitation of Tumor Progression after Anti-CD19 Chimeric Antigen Receptor T Cells Treatment in Aggressive B-Cell Lymphoma","volume":"56","author":"Danylesko","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-015-2529-2","article-title":"Systematic Review and Meta-Analysis on the Prognostic Value of Complete Remission Status at FDG-PET in Hodgkin Lymphoma after Completion of First-Line Therapy","volume":"95","author":"Adams","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/bjc.2013.338","article-title":"Limited Role for Surveillance PET\u2013CT Scanning in Patients with Diffuse Large B-Cell Lymphoma in Complete Metabolic Remission Following Primary Therapy","volume":"109","author":"Cheah","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.2014.55.7561","article-title":"Utility of Routine Post-Therapy Surveillance Imaging in Diffuse Large B-Cell Lymphoma","volume":"32","author":"Thompson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1200\/JCO.2015.62.0229","article-title":"Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study","volume":"33","author":"Jakobsen","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating Tumour DNA and CT Monitoring in Patients with Untreated Diffuse Large B-Cell Lymphoma: A Correlative Biomarker Study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_31","first-page":"1659","article-title":"DNA Fragments in the Blood Plasma of Cancer Patients: Quantitations and Evidence for Their Origin from Apoptotic and Necrotic Cells","volume":"61","author":"Jahr","year":"2001","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000226740","article-title":"Neoplastic Characteristics of the DNA Found in the Plasma of Cancer Patients","volume":"46","author":"Stroun","year":"1989","journal-title":"Oncology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/s41375-022-01618-w","article-title":"Circulating Tumor DNA in B-Cell Lymphoma: Technical Advances, Clinical Applications, and Perspectives for Translational Research","volume":"36","author":"Lauer","year":"2022","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive Monitoring of Diffuse Large B-Cell Lymphoma by Immunoglobulin High-Throughput Sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/2643-3230.BCD-21-0029","article-title":"Circulating Tumor DNA in Lymphoma: Principles and Future Directions","volume":"3","author":"Roschewski","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.13420","article-title":"Prognostic Value of Complete Remission Status at End-of-Treatment FDG-PET in R-CHOP-Treated Diffuse Large B-Cell Lymphoma: Systematic Review and Meta-Analysis","volume":"170","author":"Adams","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-018-0111-6","article-title":"Non-Invasive Monitoring of Diffuse Large B-Cell Lymphoma by Cell-Free DNA High-Throughput Targeted Sequencing: Analysis of a Prospective Cohort","volume":"8","author":"Bohers","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct Biological Subtypes and Patterns of Genome Evolution in Lymphoma Revealed by Circulating Tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","article-title":"Total Metabolic Tumor Volume, Circulating Tumor Cells, Cell-Free DNA: Distinct Prognostic Value in Follicular Lymphoma","volume":"2","author":"Dupuis","year":"2018","journal-title":"Blood Adv."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic Molecular Monitoring Reveals That SWI-SNF Mutations Mediate Resistance to Ibrutinib plus Venetoclax in Mantle Cell Lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/bloodadvances.2021006397","article-title":"Circulating Tumor DNA Predicts Therapeutic Outcome in Mantle Cell Lymphoma","volume":"6","author":"Lakhotia","year":"2022","journal-title":"Blood Adv."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8765","DOI":"10.18632\/oncotarget.14448","article-title":"The Prognostic Value of Clonal Heterogeneity and Quantitative Assessment of Plasma Circulating Clonal IG-VDJ Sequences at Diagnosis in Patients with Follicular Lymphoma","volume":"8","author":"Sarkozy","year":"2017","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An Ultrasensitive Method for Quantitating Circulating Tumor DNA with Broad Patient Coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2019.06.011","article-title":"Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction","volume":"178","author":"Kurtz","year":"2019","journal-title":"Cell"},{"key":"ref_46","first-page":"4018","article-title":"Determinants of Circulating Tumor DNA Levels across Lymphoma Histologic Subtypes","volume":"130","author":"Kurtz","year":"2017","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/hon.2704","article-title":"The Development of Liquid Biopsy for Research and Clinical Practice in Lymphomas: Report of the 15-ICML Workshop on CtDNA","volume":"38","author":"Rossi","year":"2020","journal-title":"Hematol. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/JOP.19.00691","article-title":"Potential of Circulating Tumor DNA for the Management of Patients with Lymphoma","volume":"16","author":"Huet","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e00125","DOI":"10.1016\/j.plabm.2019.e00125","article-title":"Comparison of Roche Cell-Free DNA Collection Tubes\u00ae to Streck Cell-Free DNA BCT\u00ae s for Sample Stability Using Healthy Volunteers","volume":"16","author":"Parackal","year":"2019","journal-title":"Pract. Lab Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"7526","DOI":"10.1038\/s41598-017-06106-1","article-title":"Statistical Analysis of Mutant Allele Frequency Level of Circulating Cell-Free DNA and Blood Cells in Healthy Individuals","volume":"7","author":"Xia","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","article-title":"High-Intensity Sequencing Reveals the Sources of Plasma Circulating Cell-Free DNA Variants","volume":"25","author":"Razavi","year":"2019","journal-title":"Nat. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1021\/acssensors.7b00953","article-title":"Extending Circulating Tumor DNA Analysis to Ultralow Abundance Mutations: Techniques and Challenges","volume":"3","author":"Rodda","year":"2018","journal-title":"ACS Sens."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced Detection of Minimal Residual Disease by Targeted Sequencing of Phased Variants in Circulating Tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/978-1-62703-269-8_10","article-title":"MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR","volume":"971","author":"Pott","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/asheducation-2016.1.437","article-title":"Minimal Residual Disease in Mantle Cell Lymphoma: Insights into Biology and Impact on Treatment","volume":"2016","author":"Hoster","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1101\/gr.6.10.986","article-title":"Real Time Quantitative PCR","volume":"6","author":"Heid","year":"1996","journal-title":"Genome Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.clinbiochem.2015.03.015","article-title":"Digital PCR Analysis of Circulating Nucleic Acids","volume":"48","author":"Hudecova","year":"2015","journal-title":"Clin. Biochem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1200\/JCO.2005.26.856","article-title":"Molecular Pathogenesis of Follicular Lymphoma: A Cross Talk of Genetic and Immunologic Factors","volume":"23","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"10209","DOI":"10.1073\/pnas.180316097","article-title":"Ongoing Immunoglobulin Somatic Mutation in Germinal Center B Cell-like but Not in Activated B Cell-like Diffuse Large Cell Lymphomas","volume":"97","author":"Lossos","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1073\/pnas.1205299110","article-title":"Genetic Heterogeneity of Diffuse Large B-Cell Lymphoma","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nbt.3520","article-title":"Integrated Digital Error Suppression for Improved Detection of Circulating Tumor DNA","volume":"34","author":"Newman","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse Large B-Cell Lymphoma Genotyping on the Liquid Biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e23914","DOI":"10.1016\/j.heliyon.2023.e23914","article-title":"Tackling the Implementation Gap for the Uptake of NGS and Advanced Molecular Diagnostics into Healthcare Systems","volume":"10","author":"Horgan","year":"2024","journal-title":"Heliyon"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s11864-024-01201-8","article-title":"Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: From Bench to Bedside?","volume":"25","author":"Cherng","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","article-title":"Determinants of Resistance to Engineered T Cell Therapies Targeting CD19 in Large B Cell Lymphomas","volume":"41","author":"Sworder","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.21.00377","article-title":"Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial","volume":"39","author":"Frank","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e008450","DOI":"10.1136\/jitc-2023-008450","article-title":"Dynamic Monitoring of Circulating Tumor DNA Reveals Outcomes and Genomic Alterations in Patients with Relapsed or Refractory Large B-Cell Lymphoma Undergoing CAR T-Cell Therapy","volume":"12","author":"Zou","year":"2024","journal-title":"J. ImmunoTherapy Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7457","DOI":"10.1182\/blood-2022-170629","article-title":"Circulating Tumor DNA Correlation with Lymphoma Response and Survival Outcomes at Multiple Time Points of Anti\u2014CD19 CAR T Cell Therapy","volume":"140","author":"Caimi","year":"2022","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1182\/blood-2023-178871","article-title":"Early Prediction of Treatment Response By Circulating Tumor DNA Profiling in Patients with Diffuse Large B-Cell Lymphoma Receiving CAR T-Cell Therapy","volume":"142","author":"Foerster","year":"2023","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"7160","DOI":"10.1182\/blood-2023-182999","article-title":"Clinical Utility of Circulating Tumor (Ct)DNA Quantity and Kinetics in Patients Undergoing CAR T-Cell Therapy for Relapsed\/Refractory Aggressive B-Cell Lymphoma","volume":"142","author":"Caldwell","year":"2023","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1182\/bloodadvances.2022009426","article-title":"Circulating Tumor DNA Adds Specificity to PET after Axicabtagene Ciloleucel in Large B-Cell Lymphoma","volume":"7","author":"Dean","year":"2023","journal-title":"Blood Adv."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Nijland, M., Seitz, A., Terpstra, M., van Imhoff, G.W., Kluin, P.M., van Meerten, T., Atayar, \u00c7., van Kempen, L.C., Diepstra, A., and Kok, K. (2018). Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma. Cancers, 10.","DOI":"10.3390\/cancers10110459"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1080\/10428194.2023.2220454","article-title":"Multi-Site Pre-Therapeutic Biopsies Demonstrate Genetic Heterogeneity in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma","volume":"64","author":"Hersby","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.7150\/jca.60390","article-title":"Serial Surveillance by Circulating Tumor DNA Profiling after Chimeric Antigen Receptor T Therapy for the Guidance of r\/r Diffuse Large B Cell Lymphoma Precise Treatment","volume":"12","author":"Zhou","year":"2021","journal-title":"J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"30.e1","DOI":"10.1016\/j.jtct.2021.10.007","article-title":"Assessing CAR T-Cell Therapy Response Using Genome-Wide Sequencing of Cell-Free DNA in Patients with B-Cell Lymphomas","volume":"28","author":"Goodman","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of Anti-CD19 CAR T Cell Infusion Products Associated with Efficacy and Toxicity in Patients with Large B Cell Lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"472.e1","DOI":"10.1016\/j.jtct.2023.03.009","article-title":"Cell-Free DNA Dynamic Concentration and Other Variables Are Predictors of Early Progression after Chimeric Antigen Receptor T Cell Therapy in Patients with Diffuse Large B Cell Lymphoma","volume":"29","author":"Chicano","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e5262795","DOI":"10.1097\/01.HS9.0000971388.52627.95","article-title":"P1123 Early Ctdna Clearance after Car T-Cell Infusion Predicts Outcome in Patients with Large B-Cell Lymphoma: Results from Alycante, A Phase 2 Lysa Study","volume":"7","author":"Gomes","year":"2023","journal-title":"Hemasphere"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1182\/blood-2023-181007","article-title":"Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study","volume":"142","author":"Stepan","year":"2023","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Chen, L., Mu, W., Gu, J., Xiao, M., Huang, L., Zheng, M., Li, C., Xiao, Y., Zhou, J., and Long, X. (2021). TP53-Mutated Circulating Tumor DNA for Disease Monitoring in Lymphoma Patients after CAR T Cell Therapy. Diagnostics, 11.","DOI":"10.3390\/diagnostics11050844"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-Year Follow-Up of KTE-X19 in Patients With Relapsed\/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1182\/blood-2023-188338","article-title":"Post-CAR-T Minimal Residual Disease (MRD) Monitoring in Mantle Cell Lymphoma Enables Early Relapse Detection","volume":"142","author":"Ananth","year":"2023","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1188818","DOI":"10.3389\/fimmu.2023.1188818","article-title":"Personalized Monitoring of Circulating Tumor DNA with a Specific Signature of Trackable Mutations after Chimeric Antigen Receptor T-Cell Therapy in Follicular Lymphoma Patients","volume":"14","author":"Poza","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/10428194.2018.1474463","article-title":"Circulating Tumor DNA Assessment in Patients with Diffuse Large B-Cell Lymphoma Following CAR T-Cell Therapy","volume":"60","author":"Hossain","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"7547","DOI":"10.1200\/JCO.2023.41.16_suppl.7547","article-title":"7547 Poster Session Circulating Tumor DNA (CtDNA) by ClonoSEQ to Monitor Residual Disease after Axicabtagene Ciloleucel (Axi-Cel) in Large B-Cell Lymphoma (LBCL)","volume":"41","author":"Miles","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e2300382","DOI":"10.1200\/PO.23.00382","article-title":"Recommendations for the Equitable and Widespread Implementation of Liquid Biopsy for Cancer Care","volume":"8","author":"Febbo","year":"2024","journal-title":"JCO Precis. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/10\/1881\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:42:40Z","timestamp":1760107360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/10\/1881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":87,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["cancers16101881"],"URL":"https:\/\/doi.org\/10.3390\/cancers16101881","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,15]]}}}